cardiology careers collections past issues search home
     

J Am Coll Cardiol, 1987; 9:197-203
© 1987 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroder, R
Right arrow Articles by Tebbe, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroder, R
Right arrow Articles by Tebbe, U

A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity

R Schroder, KL Neuhaus, A Leizorovicz, T Linderer, and U Tebbe

Long-term mortality and morbidity of 1,741 patients with acute myocardial infarction, treated with intravenous streptokinase (1.5 million IU/h) or placebo, was assessed in a double-blind placebo-controlled trial (ISAM). At the 7 month follow-up, 94 (10.9%) of the 859 patients in the streptokinase group and 98 (11.1%) of the 882 patients in the placebo group had died; at an average follow-up of 21 months, 14.4% of the streptokinase group and 16.1% of the placebo group had died. The differences were not statistically significant. Long-term mortality was slightly higher in patients with anterior myocardial infarction and streptokinase treatment (20.1 versus 18.4%) and lower in patients with inferior myocardial infarction (10.2 versus 14.2%). Patients with previous myocardial infarction had a higher long-term mortality rate with streptokinase (34.9 versus 21.5% with placebo, p = 0.03). At 7 months, there were significantly more cases of reinfarction in the streptokinase group (7.2 versus 4.5%, p = 0.02). It is concluded that despite a significant limitation of infarct size by intravenous streptokinase, long-term mortality is only slightly reduced and reinfarction is significantly more frequent. Both findings suggest the need for complementary therapy such as revascularization procedures after thrombolysis.


This article has been cited by other articles:


Home page
HeartHome page
C J Terkelsen, J F Lassen, B L Norgaard, J C Gerdes, T T Nielsen, and H R Andersen
Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction?
Heart, May 1, 2003; 89(5): 483 - 484.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Scrutinio, C. Cimminiello, E. Marubini, M. Vittoria Pitzalis, M. Di Biase, P. Rizzon, and the STAMI Group
Ticlopidine versus aspirin after myocardial infarction (stami) trial
J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1259 - 1265.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. G. Franzosi, E. Santoro, C. De Vita, E. Geraci, A. Lotto, A. P. Maggioni, F. Mauri, F. Rovelli, L. Santoro, L. Tavazzi, et al.
Ten-Year Follow-Up of the First Megatrial Testing Thrombolytic Therapy in Patients With Acute Myocardial Infarction : Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study
Circulation, December 15, 1998; 98(24): 2659 - 2665.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
E. Kuralay, U. Demirkilic, E. Ozal, F. Cingoz, H. Karaeren, and H. Tatar
Recovery of Left Ventricular Diastolic Function After Coronary Bypass Surgery
Asian Cardiovasc Thorac Ann, December 1, 1998; 6(4): 250 - 256.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
C. Baigent, R. Collins, P. Appleby, S. Parish, P. Sleight, and R. Peto
ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
BMJ, May 2, 1998; 316(7141): 1337 - 1343.
[Abstract] [Full Text]


Home page
Med Decis MakingHome page
J. Kellett and J. Clarke
Comparison of "Accelerated" Tissue Plasminogen Activator with Streptokinase for Treatment of Suspected Myocardial Infarction
Med Decis Making, October 1, 1995; 15(4): 297 - 310.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
J. H. Christensen, L. Ravn, S. E. Rasmussen, and H. T. Sorensen
The Effect of Streptokinase on Return to Work 18 Months After a First Myocardial Infarction
Angiology, October 1, 1995; 46(10): 923 - 928.
[Abstract] [PDF]


Home page
NEJMHome page
C. L. Grines, K. F. Browne, J. Marco, D. Rothbaum, G. W. Stone, J. O'Keefe, P. Overlie, B. Donohue, N. Chelliah, G. C. Timmis, et al.
A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction
N. Engl. J. Med., March 11, 1993; 328(10): 673 - 679.
[Abstract] [Full Text]


Home page
ScienceHome page
E Haber, T Quertermous, G. Matsueda, and M. Runge
Innovative approaches to plasminogen activator therapy
Science, January 6, 1989; 243(4887): 51 - 56.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
J. Zatuchni
Letters to the Editor and Case Reports: Postthrombolytic High-Risk Syndrome
Angiology, August 1, 1988; 39(8): 773 - 774.
[PDF]



 
  cardiology careers collections past issues search home